Skip to main content
. 2023 Apr 26;14:103. doi: 10.1186/s13287-023-03331-6

Table 3.

The intervention and outcomes of six clinical trails

Clinical trial no. Cell type and source Intervention
Experimental group (fixed cell dose) Control group
(a)
1 ASCs autologous First: 2 × 107 + fibrin glue First: fibrin glue
Second: double dose Second: double dose
2 ASCs autologous First: 2 × 107, 2 × 107 + fibrin glue First: fibrin glue
Second: double dose Second: double dose
3 BSCs allogenic Group 1: 1 × 107 Saline solution (2.5–5 ml)
Group 2: 3 × 107
Group 3: 9 × 107
4 ASCs allogenic 12 × 107 Saline solution: 24 ml
5 ASCs autologous First: 10 × 107 + fibrin glue First: Fibrin glue (2–5 ml)
Second: 10 × 107 + fibrin glue Second: Fibrin glue (2–5 ml)
6 ASCs autologous (142.3 ± 45.7) × 106 Surgery
Outcome assessment Results (healed)
 ≤ 3 months  > 3 months, ≤ 6 months 1 year (48 ~ 52 weeks)  > 1 year
(b)
Reepithelialisation; Reepithelialisation + MRI 17/24 vs. 3/25 / 15/24 vs. 3/25 7/21 vs. 2/13
Reepithelialisation + MRI 17/64, 23/60 vs. 9/59 25/64, 26/60 vs. 22/59 24/42, 22/42 vs. 19/51 /
Reepithelialisation + MRI 2/5, 4/5, 1/5 vs. 2/6 4/5, 4/5, 1/5 vs. 2/6 / 3/4, 4/4, 1/5 vs. 0/3
Reepithelialisation + MRI / 53/103 vs. 36/101 58/103 vs. 39/101 14/25 vs. 6/15
Reepithelialisation + MRI / 7/23 vs. 9/21 11/20 vs. 12/19 10/20 vs. 5/19
Reepithelialisation + MRI/ERUS 10/11 vs. 5/11 8/11 vs. 6/11 7/11 vs. 6/11 /